Case Study: Curious Case of Remicade bio-pharma patent battle with Inflectra
Posted on22 Aug 2016
Tagsbiopharma patent battle, biopharmaceuticals, Celltrion, Hospira, Inflectra, Johnson & Johnson, pfizer, Remicade, Remicade biosimilar
Comments0
Biopharmaceutical: Infliximab Class: monoclonal antibody Brand Name: Remicade Marketed By: Johnson & Johnson ——————————– Biosimilar of Infliximab is Inflectra. ——————————– Infliximab (trade... Read More